Drug Safety Communication “Close Out” Process Sought By BIO
Executive Summary
FDA’s plan to permanently archive old safety communications, even after an issue has been resolved, is not aligned with the goal of informing the public about potential emerging risks, the Biotechnology Industry Organization says in comments on a recent draft guidance. Pharmacy groups want the agency’s safety communications to include more information about the data underlying a potential risk.